Ligand id: 6778

Name: ofatumumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ofatumumab

No information available.
Summary of Clinical Use
Approved to treat chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab, or which is previously untreated. May also be beneficial in the treatment of follicular non-Hodgkin's lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. The effectiveness of ofatumumab against additional hematological malignancies is being investigated in Phase III clinical trial.
In January 2015, the FDA expanded approval to include extended treatment for CLL patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive disease.
In August 2016, the FDA expanded approval again to include use of ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).
Mechanism Of Action and Pharmacodynamic Effects
Anti-CD20 monoclonal antibody inhibiting early stage B lymphocyte activation. Binds to a different CD20 epitope than rituximab and most other anti-CD20 antibodies.